TipRanks
Pharvaris (PHVS)
NASDAQ:PHVS
US Market
PHVS
Pharvaris
RESEARCH TOOLSreports
Want to see PHVS full AI Analyst Report?

Pharvaris (PHVS) Stock News & Sentiment

193 Followers
Pharvaris: Strong Phase 3 Data for Deucrictibant XR, but Commercial Hurdles Justify Hold Despite Price Target Increase to $44
Premium
Ratings
Pharvaris: Strong Phase 3 Data for Deucrictibant XR, but Commercial Hurdles Justify Hold Despite Price Target Increase to $44
11d ago
PHVS
Pharvaris Affirmed as Emerging Oral HAE Leader on Strong Phase 3 Data; Buy Rating Reiterated with Unchanged $60 Price Target
Premium
Ratings
Pharvaris Affirmed as Emerging Oral HAE Leader on Strong Phase 3 Data; Buy Rating Reiterated with Unchanged $60 Price Target
11d ago
PHVS
Pharvaris Unveils CHAPTER-3 Phase 3 Topline Data and HAE Pipeline Milestones
Premium
Company Announcements
Pharvaris Unveils CHAPTER-3 Phase 3 Topline Data and HAE Pipeline Milestones
11d ago
6K
PHVS
Pharvaris Posts Strong Phase 3 HAE Prophylaxis Data for Oral Deucrictibant XR
Premium
Company Announcements
Pharvaris Posts Strong Phase 3 HAE Prophylaxis Data for Oral Deucrictibant XR
11d ago
6K
PHVS
Buy Rating Reaffirmed as Deucrictibant Advances Toward Key Phase 3 Readout; $52 Price Target Maintained
Premium
Ratings
Buy Rating Reaffirmed as Deucrictibant Advances Toward Key Phase 3 Readout; $52 Price Target Maintained
22d ago
PHVS
Pharvaris Posts Q2 2026 Results as Deucrictibant Nears Key Phase 3 Data and Regulatory Milestones
Premium
Company Announcements
Pharvaris Posts Q2 2026 Results as Deucrictibant Nears Key Phase 3 Data and Regulatory Milestones
1M ago
6K
PHVS
Pharvaris Shareholders Approve 2025 Accounts and Renew Board Authorities at 2026 AGM
Premium
Company Announcements
Pharvaris Shareholders Approve 2025 Accounts and Renew Board Authorities at 2026 AGM
3M ago
6K
PHVS
More PHVS News >

PHVS News on the Web

Pharvaris (PHVS) Reports an 83% HAE Attack-Rate Reduction. Can Oral Convenience Win?
Insider Monkey
Neutral
Pharvaris price target raised to $62 from $46 at Morgan Stanley
TipRanks News
Bullish
Pharvaris price target raised to $65 from $55 at Wells Fargo
TipRanks News
Bullish
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), Pharvaris (PHVS) and Zimmer Biomet Holdings (ZBH)
TipRanks News
Bullish
Biotech Stocks At 52-Week Highs - PHVS +7%, ROIV +6% On Trial Readouts, BLSM +4%, ATRC, FTH
rttnews
Bullish
Pharvaris price target raised to $75 from $50 at Oppenheimer
TipRanks News
Bullish
Buy Rating Reaffirmed as Deucrictibant Advances Toward Key Phase 3 Readout; $52 Price Target Maintained
TipRanks News
Bullish
Pharvaris Soars To New Highs On Pivotal Trial Hopes
TipRanks News
Bullish

News Score - Last 7 Days

Neutral
PHVS
Sector Average
Media Buzz
This Week4 articles
Weekly Average10.5 articles
News Sentiment
This Week100%
Sector Average91%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is PHVS’s Media Buzz Sentiment?
4 articles about PHVS were published this week. In an average week, 10.5 articles are published.
    What is PHVS’s weekly average amount of articles?
    In an average week, 10.5 articles about PHVS are published.
      What is PHVS’s News Sentiment?
      100% of articles about PHVS were positive this week, compared to its sector average of 91%.
        Healthcare Stocks that are Trending in the News
        ASNDAscendis Pharma
        CRBPCorbus Pharmaceuticals
        RVMDRevolution Medicines
        BNTCBenitec Biopharma
        GNNSFGenscript Biotech
        Showing the stocks with the most bullish news sentiment over the past week